Neuroleptic malignant syndrome in covid-19 pediatrics

Dicle Sener Okur

State Hospital of Denizli, Turkey

Received Date: 2022-03-10 | Accepted Date: 2022-03-17 | Published Date: 2022-03-24
Visit for more related articles at Pediatric Infectious Diseases: Open Access

Abstract

Neuroleptic malignant syndrome (NMS) is a clinical condition associated with the use of antipsychotics and drugs that affect the dopaminergic system, characterized by extrapyramidal symptoms, autonomic dysfunction. NMS during COVID-19 infection has not been previously described among children. In this report, we reported a paediatric patient who was followed up because of NMS developed during the COVID-19 infection course. Neuroleptic malignant syndrome (NMS) is a clinical condition associated with the use of antipsychotics and drugs that affect the dopaminergic system, characterized by extrapyramidal symptoms, autonomic dysfunction. NMS during COVID-19 infection has not been previously described among children. In this report, we reported a paediatric patient who was followed up because of NMS developed during the COVID-19 infection course.

open access journals, open access scientific research publisher, open access publisher
Select your language of interest to view the total content in your interested language

Viewing options

Flyer image

Share This Article

paper.io

agar io

wowcappadocia.com
cappadocia-hotels.com
caruscappadocia.com
brothersballoon.com
balloon-rides.net

wormax io